Can Venture Capital Help Solve America’s Maternal Health Crisis?
U.S. Startups Offer New Solutions but Raise Concerns About Medicaid Access and Equity
In Their Own Words
This Doctor Spends Hours Talking to Insurers. Her Patients Suffer The Most.
Prior Authorizations Were Meant to Cut Costs. Now They Delay Care, Says CHOP Rheumatologist
Print:
The following excerpt is from an op-ed that first appeared in the Philadelphia Inquirer on February 28th, 2024.
My patient — we’ll call her Sydney — was a young teenager who had been sick for weeks. We ultimately diagnosed her with an aggressive, rare disorder of the blood vessels that can restrict blood flow and damage vital organs.
Sydney received Remicade, a targeted, immunosuppressive medication known as a biologic during her hospitalization, and it worked. Her fevers abated, her energy returned, and her labs showed dramatic improvement. Yet, despite Sydney’s visible improvement during her hospital stay, her insurance provider denied payment for her Remicade treatments when she went home.
After an initial letter explaining the necessity of her medication, followed by a 75-minute phone call with Sydney’s insurance company three weeks later, we ultimately got her medication approved, four weeks after we prescribed it. Fortunately, Sydney was only one day late for her monthly dose.
Unfortunately, I have many other patients whose struggles with insurance over medication coverage haven’t ended so well.
As a pediatric rheumatologist, I care for children with rare forms of chronic illness for which we now have highly effective therapies. But too often, my patients can’t access these effective therapies because insurers put up many barriers to coverage.
Read the entire op-ed here.
Author
Dori Abel, MD
Fellow, Pediatric Rheumatology, Children’s Hospital of Philadelphia
More on Health Care Access & Coverage
“High-Deductible Health Plans Are Not the Answer”
They Cut Health Spending at First but Don’t Slow Long-Term Growth Rate, LDI Fellows Say
Understanding CMS’s Proposed Rule Regarding Prior Authorization For Drugs
LDI Expert Considers Cost, Quality, and Access Implications
Congress is Fighting the Wrong Pharmacy Battle
Better Plan Choices Would Lower Drug Costs, Not PBM Breakups, LDI’s Mark Pauly Says
Why Some Family Health Insurance Is Now Much Pricier
LDI Expert Proposes Fixes to Keep Marketplace Plans Within Families’ Budgets
Despite Coverage Requirements, Insurers Added Barriers to Access for Drugs
Chart of the Day: Medicare, Medicaid, and Insurers Replaced High Costs With More Hurdles, LDI Expert Finds